Name: PT 141
SKU: 350
Availability: InStock

PT-141 (Bremelanotide)

Libido, Well-being & Sexual Function – Scientific Overview, Mechanism, Clinical Use and Evidence

Scientific Overview

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist developed for the treatment of hypoactive sexual desire disorder (HSDD). Unlike PDE5 inhibitors, which act primarily through peripheral vasodilation pathways, PT-141 acts centrally to modulate sexual desire and arousal. It is an FDA-approved drug (as bremelanotide injection) for premenopausal women with acquired, generalized HSDD.

Mechanism of Action

PT-141 activates melanocortin receptors, particularly MC4R (and related melanocortin pathways) in the central nervous system. Key characteristics:

• Central melanocortin signaling modulates sexual motivation and arousal circuitry
• Does not rely on nitric oxide–mediated vasodilation
• Differentiates from PDE5 inhibitors mechanistically
• Supports clinical use where desire/arousal pathways are central drivers

Biological and Clinical Effects

Randomized controlled trials in premenopausal women with HSDD demonstrated improvements in sexual desire and reductions in distress related to low desire compared with placebo. Effects are typically observed as acute, on-demand improvements rather than continuous baseline changes.

Time of Use / Treatment Duration

PT-141 is typically used on-demand rather than as a daily therapy. In clinical practice, response is assessed over several attempts (e.g., 4–8 uses) to determine benefit, tolerability, and appropriateness for continued use. If no meaningful benefit is observed, discontinuation is generally recommended.

Safety, Tolerability, and Precautions

Common adverse effects include nausea (dose-related), flushing, headache, and injection-site reactions. PT-141 can cause transient increases in blood pressure and decreases in heart rate; avoid or use with caution in uncontrolled hypertension or significant cardiovascular disease. Contraindications may include pregnancy and severe cardiovascular disease.

Detailed References

Kingsberg SA, et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology, 134(5), 899–908.

Clayton AH, et al. (2016). Bremelanotide efficacy and safety for female sexual dysfunction: clinical trial review. Journal of Sexual Medicine, 13(11), 1705–1716.

FDA (2019). FDA approves bremelanotide injection for acquired, generalized HSDD in premenopausal women.

Diamond LE, et al. (2013). Melanocortin receptor modulation and sexual function: mechanistic rationale for bremelanotide. CNS Drugs, 27(3), 209–220.

LaValle J. The Complete Guide to Peptides / Peptide Therapy. Clinical-functional framing for libido, neuroendocrine balance, and peptide-assisted sexual wellness.

Posology (Clinical Practice–Oriented)

FDA-approved regimen (HSDD in premenopausal women):

• 1.75 mg subcutaneously, administered as needed at least 45 minutes before anticipated sexual activity
• Maximum: 1 dose within 24 hours; no more than 8 doses per month

Clinicians should follow the official prescribing information for warnings and contraindications.

Clinical Practice Framing (Libido, Well-being & Sleep Context)

In a libido and well-being framework, PT-141 is positioned as a central desire/arousal modulator appropriate for carefully selected patients. It should be integrated into a broader evaluation of libido drivers: endocrine status, relationship factors, mood/anxiety, sleep quality, pain, medications (SSRIs), and metabolic health.

The peptides described in this material are intended strictly for research purposes only. They are not approved for human or veterinary use, clinical application, diagnosis, treatment, or prevention of any disease.

Any research involving these compounds must be conducted in compliance with applicable laws and regulations in the country where the research is performed, including prior approval by a duly constituted Ethics Committee or Institutional Review Board (IRB), where required.

RegenPept acts solely as a supplier of research-grade materials and assumes no responsibility or liability for the design, conduct, regulatory compliance, interpretation, or outcomes of any research involving these products.

Any dosage, administration protocols, or related information contained in this material are derived from publicly available scientific literature and are provided strictly for informational purposes. Such information does not constitute medical advice, therapeutic recommendation, or endorsement of any specific use by RegenPept.